Expression and characterisation of recombinant human collagen (COMA)

Font Standard Bold
Login

Research unit

INNOSUISSE

Project number

9760.1;3 PFLS-LS

Project title

Expression and characterisation of recombinant human collagen (COMA)

Texts for this project

	German	French	Italian	English
Short description	-	-	-
Abstract	-	-	-

Inserted texts

Category	Text
Short description (English)	Expression and characterisation of recombinant human collagen (COMA)
Abstract (English)	In ubiquitous use, collagens are extracted and purified from natural sources. The non-uniformity of such raw materials, being composed of several different collagen types, and safety concerns hamper their use for biomaterials or pharmaceuticals. To overcome these obstacles, recombinant technology will be trialled. Samples of rh-procollagen (with intact triple helix structure) to be used for prototyping new medical materials (e.g. synthetic tissues) will be gained from high-cell-density processes with a yeast expression system. Moreover, the experimental data collected will provide first estimates of manufacturing costs in terms of (i) raw materials and (ii) capability figures for the cultivation, downstream and further biosynthetic processing needed to achieve the mature functional form required.

Category

Text

Short description
(English)

Expression and characterisation of recombinant human collagen (COMA)

Abstract
(English)

In ubiquitous use, collagens are extracted and purified from natural sources. The non-uniformity of such raw materials, being composed of several different collagen types, and safety concerns hamper their use for biomaterials or pharmaceuticals. To overcome these obstacles, recombinant technology will be trialled. Samples of rh-procollagen (with intact triple helix structure) to be used for prototyping new medical materials (e.g. synthetic tissues) will be gained from high-cell-density processes with a yeast expression system. Moreover, the experimental data collected will provide first estimates of manufacturing costs in terms of (i) raw materials and (ii) capability figures for the cultivation, downstream and further biosynthetic processing needed to achieve the mature functional form required.